In fact, in a stage Ib/II trial of combined cetuximab and pembrolizumab treatment for patients with advanced CRC, the combination treatment of cetuximab with pembrolizumab significantly increased the density of CD3+, CD8+, and CTLA-4+ lymphocytes and natural killer cells in tumors. The gene discussed is CTLA4; the disease is colorectal carcinoma.